drugset / Trial / NCT02522221

Tecarfarin Anti-Coagulation Trial (TACT)

NCT02522221

Phase 3 Unknown 1000 enrolled Espero Biopharma
RandomizedParallel-groupOpen-labelTreatment

Summary

TACT is a "real world" randomized controlled trial of tecarfarin, a novel vitamin K antagonist, vs. warfarin. The quality of anticoagulation control will be compared for the two groups of subjects who require chronic oral anticoagulation for a broad panel of indications.

Timeline

Start
2018-06-01
Primary completion
2019-03-30
Completion
2019-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tecarfarin Small molecule Oral
Comparator Warfarin Small molecule Oral

Indications